Bioaffinity Technologies Inc.
13F holders, Q4 2024 (December 31)16holders +2
3new positions
1sold out
1famous investor
$0.93avg. 13F price*
At the end of Q4 2024, 16 institutions reported holding Bioaffinity Technologies Inc. in their 13F filings, up 2 from Q3 2024. 3 opened new positions and 1 sold out. The largest holders were Vanguard Group Inc. ($244K), Geode Capital Management, LLC ($93K) and Sheaff Brock Investment Advisors, LLC ($42K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Bioaffinity Technologies Inc.
- CUSIP
- 09076W109
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $28K |
| Exits | 1 | $208 |
All 13F filers, Q3 2024 → Q4 2024: 73,070 shares bought and 5,209 shares sold, net +67,861 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Vanguard Group Inc. | 0.00% | No change | 260,869 | $244K |
| Geode Capital Management, LLC | 0.00% | Add +14.2% | 99,551 | $93K |
| Sheaff Brock Investment Advisors, LLC | 0.00% | Add +131.5% | 46,304 | $42K |
| Captrust Financial Advisors | 0.00% | No change | 27,885 | $25K |
| State Street Corp. | 0.00% | No change | 17,600 | $16K |
| Two Sigma Securities, LLC | 0.00% | New | 14,420 | $13K |
| Northern Trust Corp. | 0.00% | No change | 13,662 | $12K |
| Citadel Advisors | 0.00% | New | 13,264 | $12K |
| Creative Planning | 0.00% | No change | 12,095 | $11K |
| XTX Topco Ltd | 0.00% | Reduce -5.8% | 10,616 | $10K |
| IFP Advisors, Inc | 0.00% | No change | 10,000 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +203.7% | 6,332 | $6K |
| Oarsman Capital, Inc. | 0.00% | New | 2,448 | $2K |
| Morgan Stanley | 0.00% | Reduce -89.9% | 500 | $455 |
| Bank of America Corp. | 0.00% | Add +25.4% | 84 | $76 |
| JPMorgan Chase & Co. | 0.00% | No change | 21 | $20 |
"% of holder's portfolio" is BIOAFFINITY TECHNOLOGIES INC's weight in each manager's 13F, not the share of Bioaffinity Technologies Inc. the manager owns.